<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Feb. 18, 2020 (HealthDay News) — Maximal resection of a contrast-enhanced (CE) tumor is associated with improved overall survival in patients with isocitrate dehydrogenase gene 1 or 2 (IDH<\/i>)-wild-type and IDH<\/i>-mutant subtype glioblastomas, according to a study published online Feb. 6 in JAMA Oncology<\/i>.<\/p>\n
Annette M. Molinaro, Ph.D., from the University of California in San Francisco, and colleagues examined the prognostic importance of maximal resection of glioblastomas in a retrospective, multicenter cohort study. Data were included for a development cohort (761 patients with 9.6 years of follow-up) and for two external validation cohorts (107 patients with 5.7 years of follow-up and 99 patients with a median follow-up of 10.9 months).<\/p>\n
The researchers found that in the development cohort, survival was similar for younger patients with IDH<\/i>-wild-type tumors and aggressive resection of CE and non-contrast-enhanced (NCE) tumors and for those with IDH<\/i>-mutant tumors (median overall survival, 37.3 months). Worse survival was seen for younger patients with IDH<\/i>-wild-type tumors and reduction of CE tumor but residual NCE tumors (median overall survival, 16.5 months). CE tumor reduction was beneficial for older patients with IDH<\/i>-wild-type tumors (median overall survival, 12.4 months). In two external cohorts, the results were validated.<\/p>\n
“Although these data show a survival benefit associated with maximal resection, it remains critically important that we do our best to remove [a] tumor in a manner that will not harm the patient,” a coauthor said in a statement.<\/p>\n
Several of the authors disclosed financial ties to the biopharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n